AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33152308
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy after chemoradiotherapy
Trial: 32179241
Drug: Anthocyanins 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins 320 mg/day
Trial: 32179241
Drug: Anthocyanins 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins 40 mg/day
Trial: 32179241
Drug: Anthocyanins 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins 80 mg/day
Trial: 32179241
Drug: Anthocyanins (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanins (all doses)
Trial: 32041913
Drug: Ciplukan extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciplukan extract 3 x 250 mg/day for 12 weeks
Trial: 34911721
Drug: Experimental therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapy (specifics not provided)
Trial: 36181377
Drug: Sugammadex (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (8 mg∙kg−1)
Trial: 36181377
Drug: Sugammadex (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2 mg∙kg−1 and 4 mg∙kg−1)
Trial: 36181377
Drug: Neostigmine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.03 mg∙kg−1)
Trial: 32538746
Drug: TACE in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE in combination with lobaplatin
Trial: 32538746
Drug: TACE in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE in combination with cisplatin (Control group)
Trial: 33057999
Drug: Physician-directed replacement
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-directed replacement (any choice of steroid, dose or route)
Trial: 33057999
Drug: Fixed-dose dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed-dose dexamethasone 8 mg oral before starting docetaxel
Trial: 34694223
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FC; 1,000 mg, single dose)
Trial: 34694223
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (IS; 200 mg every 48 hours until covering the total iron deficit or discharge)
Trial: 32053119
Drug: SMS text
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMS text messaging intervention (CARE+ Corrections), participants received weekly or daily SMS text messages for 6 months.
Trial: 33538999
Drug: Patients' Own
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients' Own Medicines (POMs)
Trial: 32213517
Drug: 12-week group
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week group cognitive-behavioural therapy (CBT) programme
Trial: 32812129
Drug: Nd:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG laser combined with intralesional steroid (Triamcinolone acetonide)
Trial: 35170392
Drug: Salinomycin (69
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salinomycin (69 mg/kg feed)
Trial: 35170392
Drug: Encapsulated Butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated Butyrate (EB) (500 mg/kg)
Trial: 35170392
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no dietary supplement)
Trial: 32450901
Drug: Training programme
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training programme (5-day training including evidence-based medicine training module and application of the guideline)
Trial: 37523429
Drug: Repeated low-level
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated low-level red-light (RLRL) therapy
Trial: 37099298
Drug: RLRL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLRL therapy
Trial: 35922823
Drug: Endoscopic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic intervention (endoscopic bulking injections)
Trial: 33500258
Drug: PD-1 inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitors (treatment duration: median 11.1 months)
Trial: 32083290
Drug: Adjuvant S1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant S1 therapy
Trial: 32083290
Drug: Modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFIRINOX regimen as adjuvant therapy
Trial: 33591032
Drug: ADASCs alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADASCs alone (3 × 10⁶ cells/1 mL) in Group 1 (n = 5)
Trial: 33591032
Drug: 120-μm lamina
RxNorm normalized name: CROSPOVIDONE (120 .MU.M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120-μm lamina recellularized with ADASCs (1 × 10⁶ cells/1 mL) in Group 3 (n = 4)
Trial: 34271931
Drug: Perceptions of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceptions of diarrhoea treatment
Trial: 35462408
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment based on patient goals and values
Trial: 34591549
Drug: panic control
RxNorm normalized name: BENZALKONIUM CHLORIDE 1 g in 59 mL TOPICAL GEL [Donut Panic Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panic control treatment (PCT)
Trial: 37574610
Drug: LEM5 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEM5 (5 mg)
Trial: 37574610
Drug: LEM10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEM10 (10 mg)
Trial: 35770861
Drug: Multinutrient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multinutrient treatment
Trial: 35123779
Drug: 1‐flunixin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐flunixin group (1‐FLU, n = 26) with a single administration of transdermal flunixin meglumine at disbudding
Trial: 35123779
Drug: 2‐flunin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐flunin group (2‐FLU, n = 24) with 2 administrations of transdermal flunixin meglumine, the first treatment at disbudding and the second 6 h after disbudding
Trial: 34675472
Drug: Oxymetazoline 0.1%
RxNorm normalized name: OXYMETAZOLINE 0.1% (PF) SOLN,OPH,UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline 0.1% ophthalmic solution, administered once daily for 14–84 days
Trial: 34675472
Drug: Placebo (vehicle),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle), administered once daily for 14–84 days
Trial: 34675472
Drug: Oxymetazoline 0.1%
RxNorm normalized name: OXYMETAZOLINE 0.1% (PF) SOLN,OPH,UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline 0.1% ophthalmic solution
Trial: 32599131
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel applied to abdominal area (treatment group A)
Trial: 32599131
Drug: 1.62% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.62% testosterone gel applied to upper arms/shoulders (treatment group B)
Trial: 35774276
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of sweet almond oil (126 ml over 7 sessions in 2 weeks, 18 ml every other day)
Trial: 35774276
Drug: Abdominal massage
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal massage with sweet almond oil (same amount as oral group, during 7 sessions in 2 weeks)
Trial: 35774276
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of sweet almond oil
Trial: 33974129
Drug: 150 µg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 µg/d iodine
Trial: 33974129
Drug: 300 µg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 µg/d iodine
Trial: 34034960
Drug: Gradual adaptation
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual adaptation (4 h on the first day, increasing by 2 h daily until 10 h)
Trial: 35002557
Drug: Inhaled Budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Budesonide (BUD) 2 mL, 0.25‐mg/mL suspension, inhalation, twice daily for 5 days
Trial: 35002557
Drug: Placebo (humidified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (humidified distilled sterile water inhalation, 2 mL)
Trial: 34452681
Drug: Behavioral Therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Therapy Team (BTT) intervention consisting of individual information-gathering sessions followed by 12 weeks of group ERP and concurrent home-based coaching sessions
Trial: 34452681
Drug: Behavioral Therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Therapy Team (BTT) intervention
Trial: 32372186
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri LR92 DSM 26866 (1 × 10^8 CFU daily for 4 weeks)
Trial: 32372186
Drug: Placebo (9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (9% glucose solution for 4 weeks)
Trial: 33763126
Drug: Neurological music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurological music therapy
Trial: 36063826
Drug: EV 4
RxNorm normalized name: Zirabev 400 MG in 16 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV 4 mg/d
Trial: 36063826
Drug: EV 6
RxNorm normalized name: Emeprev 60 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV 6 mg/d
Trial: 36063826
Drug: EV 9
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV 9 mg/d
Trial: 35635201
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of negatively charged polystyrene microspheres (NCMs)
Trial: 32171252
Drug: Network-offered training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Network-offered training programs focusing on best practice guideline-oriented use of antibiotics
Trial: 35941669
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg atorvastatin once daily for 28 days
Trial: 32895226
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 1.5 mg bolus given every 10 min until NRS pain score <4
Trial: 32895226
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus morphine 0.05 mg/kg body weight followed by 0.025 mg/kg/hour intravenous infusion
Trial: 33400384
Drug: Reminiscence therapy-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy-based care program (RTCP)
Trial: 32617881
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG injection 36 hours before oocyte retrieval
Trial: 32617881
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa) injection 36 hours before oocyte retrieval
Trial: 32617881
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection 36 hours before oocyte retrieval
Trial: 33020080
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HLS-EU-Q16 and NVS measures.
Trial: 34063322
Drug: Taurisolo� (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurisolo� (20 mg/Kg/die)
Trial: 34063322
Drug: Taurisolo� (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurisolo� (400 mg twice daily for 8 weeks)
Trial: 35587723
Drug: 0.1% HA2k
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% HA2k lotion
Trial: 35587723
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control lotion
Trial: 35587723
Drug: 0.1% HA2k
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% HA2k solution
Trial: 33934058
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (docetaxel, oxaliplatin, capecitabine; Arm A)
Trial: 33934058
Drug: No induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No induction chemotherapy (Arm B)
Trial: 33934058
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (Arm A)
Trial: 34016350
Drug: N-acetyl-l-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-l-cysteine (NAC) 1000 mg/kg in basal diet
Trial: 34397100
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate
Trial: 32048384
Drug: Personal consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal consumption of hypnotic drugs
Trial: 32048384
Drug: Personal consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal consumption of anxiolytics
Trial: 32048384
Drug: Personal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal drug consumption
Trial: 34432008
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens alone or combined with estrogen-progestin therapy
Trial: 34432008
Drug: Transdermal routes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal routes of HT administration
Trial: 34432008
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with natural progesterone
Trial: 34432008
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of HT
Trial: 32055041
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg intravenous)
Trial: 33589311
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group 2) - advised to take a liquid diet of their own choice, including shakes, juices, and milk, along with protein supplements.
Trial: 32102557
Drug: Intensity-modulated radiotherapy
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiotherapy (IMRT) using pre-induction chemotherapy (IC) images (Group A)
Trial: 32102557
Drug: Intensity-modulated radiotherapy
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiotherapy (IMRT) using post-induction chemotherapy (IC) images (Group B)
Trial: 36410799
Drug: Active transdermal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transdermal glyceryl trinitrate
Trial: 35929990
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C (1.5 g/kg/d, intravenously for 3 hours from D1 to D3) plus FOLFOX +/- bevacizumab
Trial: 35929990
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C plus FOLFOX +/- bevacizumab
Trial: 33825412
Drug: Integrated Traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Traditional Chinese and Western Medicine (IM)
Trial: 33398361
Drug: Nonvitamin K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonvitamin K oral anticoagulants (NOACs)
Trial: 34043064
Drug: Diphenhydramine 0.5
RxNorm normalized name: DIPHENHYDRAMINE 0.5%/HC 0.5% SPRAY,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 0.5 mg/kg before anesthesia induction
Trial: 34097062
Drug: EQW/DAPA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQW/DAPA (2 mg weekly/10 mg daily)
Trial: 34097062
Drug: PHEN/TPM (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHEN/TPM (7.5 mg/46 mg ER daily)
Trial: 34097062
Drug: EQW (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQW (2 mg weekly)
Trial: 34097062
Drug: DAPA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPA (10 mg daily)
Trial: 34097062
Drug: DAPA/MET (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPA/MET (10 mg/2000 mg XR daily)
Trial: 33497408
Drug: Pain treatment
RxNorm normalized name: ARNICA MONTANA FLOWER 10 g in 50 g / SALIX ALBA BARK 15 g in 50 g / FRANKINCENSE 10 g in 50 g TOPICAL CREAM [HOUKEA Bone Pain Treatment Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain treatment groups
Trial: 32650683
Drug: ATG (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG (4.5 mg/kg thymoglobulin plus cyclosporine [CsA], methotrexate [MTX], and mycophenolate mofetil [MMF])
Trial: 35139937
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no platelet-rich plasma gel)
Trial: 33030582
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (250 mg/day)
Trial: 32293362
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy (CROSS regimen): paclitaxel 50 mg/m2; carboplatin (AUC = 2), q1w, 5 cycles; concurrent radiotherapy, 41.4 Gy/23 F, over 5 weeks
Trial: 32293362
Drug: Neoadjuvant chemotherapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy: paclitaxel 175 mg/m2; cisplatin 75 mg/m2, q21d, 2 cycles
Trial: 35343294
Drug: Patient adherence
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient adherence to medication and care
Trial: 32520820
Drug: Guided internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-delivered pain management treatment
Trial: 33772757
Drug: One year
RxNorm normalized name: Annovera 0.15 MG / 0.013 MG per 24HR One Year Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One year of antiseizure medication (ASM) therapy
Trial: 33772757
Drug: Three years
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three years of antiseizure medication (ASM) therapy
Trial: 33772757
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of initial ASM treatment
Trial: 32544121
Drug: Modeled-WALANT state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modeled-WALANT state (after 10 mL of 1% lidocaine injection)
Trial: 35352668
Drug: Peri-urethral injection
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-urethral injection of autologous mucosa stem cells
Trial: 33637835
Drug: Second-generation antipsychotic
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotic (risperidone or paliperidone)
Trial: 35081130
Drug: Blended Acceptance
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended Acceptance and Commitment Therapy (ACT)
Trial: 33769293
Drug: Face-to-face Cognitive
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face Cognitive Behavioral Therapy (CBT)
Trial: 34742136
Drug: n3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n3 PUFA (930 mg EPA + 660 mg DHA)
Trial: 32089006
Drug: Alirocumab (75-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75-150 mg every 2 weeks)
Trial: 35239547
Drug: 1600 mg
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg single-dose oral cannabidiol
Trial: 32653074
Drug: Medium-dose MF–IND–GLY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose MF–IND–GLY (80 μg, 150 μg, 50 μg)
Trial: 32653074
Drug: High-dose MF–IND–GLY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MF–IND–GLY (160 μg, 150 μg, 50 μg)
Trial: 35848622
Drug: Minocycline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline treatment
Trial: 32662833
Drug: Yoga or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga or Physical Therapy (PT)
Trial: 32662833
Drug: Yoga or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga or PT (with pain medication)